Cas No. 1269440-69-8, tert-butyl 5-chloro-2-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylcarbamate

Encorafenib, a potent BRAF inhibitor, has demonstrated remarkable efficacy in treating patients with advanced melanoma harboring BRAF mutations. Our meticulously crafted intermediates ensure a seamless manufacturing process, enabling the timely production and supply of this life-saving medication. Join forces with us to revolutionize cancer care, providing patients with renewed hope and improved outcomes. Together, let's pave the way for a brighter future with Encorafenib.